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Transglutaminases (TGs) are Ca2þ -dependent enzymes capable of catalyzing transamidation of glutamine
residues to form intermolecular isopeptide bonds. These enzymes are involved in various biological
phenomena, including blood coagulation, wound healing, cell death, tissue repair, and terminal differentiation
of keratinocytes. Among the TG-family members, TG5 is one of the latest identified enzymes and therefore the
less characterized at the functional level. In this work, we reported that TG5 is proteolytically processed in the
baculovirus expression system and in mammal epithelial cells. Similar to other members of the TG family—TG1,
TG3, and factor XIIIa -, TG5 full-length enzyme has very low enzymatic activity, while the 53-kDa proteolytically
processed form is highly active.
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INTRODUCTION
Transglutaminases (TGs: EC 2.3.2.13) constitute a family of
Ca2þ -dependent enzymes that covalently cross-link proteins
by catalyzing the formation of isopeptide bonds between the
g-carboxyamide group of glutamine and the e-amino group
of lysine (Greenberg et al., 1991; Griffin et al., 2002; Lorand
and Graham, 2003; Candi et al., 2005; Eckert et al., 2005;
Esposito and Caputo, 2005). Resulting cross-linked bonds are
covalent, stable, and resistant to proteolysis.
To date, nine members of the family are known: TG1–TG7,
factor XIII, and band 4.2. TGs are involved in various
biological phenomena, including blood coagulation, wound
healing, cell death, tissue repair, terminal differentiation of
keratinocytes, signaling, and vesicle trafficking (Lorand et al.,
2003; Candi et al., 2005; Eckert et al., 2005).
Among the TG-family members, TG5 is one of the latest
identified enzyme together with TG6 and TG7 (Aeschlimann
et al., 1998), and therefore the less characterized at the
functional level. TG5, similar to TG1 and TG3, is expressed
in stratified squamous epithelia such as the upper layers of
the epidermis (Candi et al., 2002) and in human hair follicle
(Thibaut et al., 2005), and possibly is also responsible for
formation of the cornified cell envelope (Candi et al., 2001,
2005; Kalinin et al., 2002). As TG1 and TG3, TG5 cross-links
small proline-rich proteins, loricrin, and involucrin in in vitro
cross-linking experiments, and uses specific glutamine and
lysine residues (Candi et al., 2001; Hitomi et al., 2001) in
the same protein substrate, suggesting that it acts together
with TG1 and TG3 to generate a functional cell envelope.
The low solubility of TG5 expressed both in the baculo-
virus system and in keratinocytes is not due to membrane
binding by lipid modification, but probably to its interaction
with vimentin network (Candi et al., 2001). In addition, three
different TG5 human splicing isoforms are known, in
accordance with TG2 and TG3 (Aeschlimann et al., 1998;
Candi et al., 2001; Citron et al., 2001; Zocchi et al., 2007).
The enzyme is also able to bind and hydrolyze guanosine
triphosphate like TG2 and TG3 (Liu et al., 2002; Ahvazi et al.,
2003; Ahvazi et al., 2004a, b; Candi et al., 2004). Native TG5
contains 725 amino acids corresponding to a molecular mass
of 81 kDa, both in human and mouse (Aeschlimann et al.,
1998); mutations of the human sequence that abolish its
activity, are associated to acral peeling skin syndrome (APPS,
MIM 609796; Cassidy et al., 2005).
Proteolytic activation in TG-family members is a common
feature: factor XIII, TG1, and TG3 are subjected to proteolysis
from specific proteases; in all cases, the proteolytic cleavage
generates more active enzyme. Blood coagulation factor XIII
(FXIII) is a zymogen of tetrameric structure (A2B2) containing
two potentially active A-subunits (FXIII-A) and two inhibitory/
carrier B-subunits (FXIII-B). Plasma FXIII is transformed into
active TG (FXIIIa) by the concerted action of thrombin and
Ca2þ in the final phase of the coagulation cascade (Muszbek
et al., 1996, 1999; Shemirani et al., 2006). TG1 is mostly
expressed in the upper spinous and granular layer of stratified
squamous epithelia (Thacher and Rice, 1985; Thacher, 1989;
Hohl et al., 1998); it has a full-length, membrane-bound form
of low specific activity, and two proteolytically processed
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forms, mostly cytosolic, with 5- to 10-fold higher specific
activities (Kim et al., 1995). During terminal differentiation,
part of TG1 is proteolytically processed at Gly93 and Gly573
into highly active 67/33/10-kDa fragments, while still
anchored to membranes (Kim et al., 1995; Steinert et al.,
1996a). Among various proteases in differentiating keratino-
cytes, m-calpain and m-calpain, calcium-dependent intra-
cellular proteases, as well as the bacterial enzyme, dispase,
proteolyze TG1 in vitro into 67/33/10-kDa fragments, with
specific activity remaining unaltered before and after proteo-
lysis (Hitomi et al., 2000). During keratinocyte differentiation,
TG3 is also activated by limited proteolysis of a 77-kDa
zymogen into two 47- and 30-kDa fragments, in a region
between the catalytic core and the b-barrel-1, located on
the 462- to 471-amino-acid sequence range (Ahvazi et al.,
2003, 2004a). This process is controlled by cystatin M/E, at
least during skin morphogenesis in the neonatal phase.
In vitro, cathepsin-L (Cheng et al., 2006), like the bacterial
enzyme dispase (Kim et al., 1990; Hitomi et al., 1999), is able
to proteolyze the zymogen form, resulting in proteolytic
activation of TG3.
To further investigate the biochemical properties of TG5,
we have expressed the full-length enzyme in the baculovirus
system, in keratinocytes, and in human embryonic kidney-
293 (HEK-293) cells. In all of these systems, we have found
that TG5 is subjected to proteolysis, which activates the
enzyme itself.
RESULTS
Active TG5 extraction and IMAC purification
About 70% of TG5 expressed both in the baculovirus system
and in keratinocytes is insoluble in non-ionic detergents
(1% Triton X-100 (TX-100)/Nonidet P40 (NP-40); Candi et al.,
2001). Successful total extraction can be obtained only using
ionic denaturants such as SDS and urea. The low solubility of
TG5 is not due to lipid modification, but probably its
interaction with vimentin network (Candi et al., 2001).
Active TG5 enzyme was recovered with sequential extrac-
tions from the pellet with a 1% TX-100/NP-40 buffer at
different extraction times ranging from 1 to 24 hours. The
highly enriched semi-purified active TG5 fractions, kept at
4 1C, retain 80% of their activity over 2–3 weeks of storage.
To purify active TG5, immobilized-metal affinity chroma-
tography (IMAC) was performed on 1% TX-100/NP-40-
extracted protein, using his-tag located on the protein
sequence C-terminal end (transglutaminase-5 C-terminus
his/c-myc tagged cDNA (TG5(C)); Figure 1). Surprisingly,
following purification, enzymatic activity analysis on both
unbound and eluted fractions revealed that only the first
fractions was active (Figure 1a), whereas western blot
analysis on the same samples, using an anti-c-myc antibody,
indicated that TG5 was present only in the eluted fraction
(Figure 1b). This experiment suggested that the C-terminal
his-tag had been cleaved from the enzyme before purifica-
tion. To further study this observation, we solubilized
TG5 enzyme by sequential extractions from the pellet with
a 1% TX-100/NP-40 buffer at different extraction time points
(15minutes, 1, 3, and 24 hours); again, most of the activity
was present in soluble fractions upon extraction for 3 and
24 hours (Figure 2a). Western blot analysis of soluble and
insoluble C-terminal his-myc TG5 fractions, using a specific
anti-c-myc antibody, revealed that full-length TG5 was more
abundant in the insoluble fraction, that was the less active
(Figure 2b), suggesting that presence of a TG5 C-terminal
truncated fragment retains the majority of the enzymatic
activity. To purify the active C-terminal truncated TG5 frag-
ment, we prepared another TG5 construct with a his-myc tag
at its N-terminus, TG5(N). Active soluble fractions were
extracted from the baculovirus system and purified by IMAC,
as mentioned above. Activity distribution was similar to
C-terminal his-myc sample activity, with the highest values in
fractions obtained after 3 and 24 hours of TX-100/NP-40
buffer extraction (Figure 2c), suggesting that his-myc tag posi-
tion at N- or C-termini did not influence either activity or TG5
solubility. Western blot analysis of active soluble fractions,
using anti-c-myc antibody, revealed that TG5 53-kDa frag-
ment increased in active fractions in parallel to the increasing
activity (Figure 2d); the full-length protein was present only in
the less active insoluble fraction.
TG5 is proteolyzed in two fragments of 53 and 28 kDa
in the baculovirus system
The identification of an N-terminal active 53-kDa fragment,
co-purifying with the full-length protein, is unquestionably
a sign that a proteolytic process allows a protein cleavage
at around 2/3 of the enzyme sequence, generating
an active 53-kDa N-terminal fragment consisting of the
enzyme N-terminus and catalytic domains lacking the
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Figure 1. IMAC on active TG5 fractions. SF9 cells were infected with
C-terminal his/c-myc TG5 recombinant baculovirus; the pellet was lysed first
with 0.1% TX-100 buffer (15minutes), then with a 1% TX-100/1% NP-40
buffer as described previously (Candi et al., 2001). The TG5 soluble fraction
was purified with cobalt IMAC resin as described under Materials and
Methods, using his-tag located on protein sequence C-terminal end. TG
activity of the soluble and the insoluble fractions one was determined by
measuring incorporation of 3H-labeled putrescine into N,N-dimethylcasein.
TG activity is reported as picomoles of putrescine cross-linked with milligram
of total protein per hour. (a) Enzymatic activity analysis on unpurified
(input, column 1), unbound (NB, column 2), and eluted fraction (E, column 3)
revealed that only the first two fractions were active, whereas (b) from
western blot analysis on the same samples, using anti-c-myc antibody,
TG5 was present only in the eluted fraction.
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28-kDa C-terminal regulatory domain (b-barrel-1 and
b-barrel2 domains). To demonstrate this finding, we repeated
western blot analysis using active soluble and insoluble
fractions, loading samples at the same concentration, and
revealing the enzyme with a specific polyclonal rat antibody.
The anti-TG5 antibody was produced in our laboratory using
as immunogen full-length enzyme extracted with SDS buffer
from the baculovirus system and purified with IMAC (Candi
et al., 2002). Western blot analysis showed a 53-kDa band
increasing in intensity in the active fractions in proportion to
increasing activity (Figure 3a), as well as the existence of
a 28-kDa band.
To identify the exact cleavage site, we performed mass
spectrometry analysis of the IMAC-purified 28-kDa TG5
fragment. The results obtained reveal that the most N-terminal
peptide in the 28-kDa TG5 fragment sequence that was
identified in tryptic digested mixture was Thr495–Lys509
(data not shown). The mass spectrometry data were not
sufficient to evaluate the exact proteolytic site corres-
ponding to His494–Thr495 because of the absence of cross-
experimental analysis between full-length TG5 and its
smaller fragment. Therefore, to say that the 28-kDa TG5
fragment corresponds to the Thr496–Leu720 peptide with
a theoretical mass of 28.24 kDa, is absolutely speculative,
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Figure 2. TG5 is proteolyzed in two 28- and 53-kDa fragments in the baculovirus system. SF9 cells were infected with recombinant baculovirus bearing the
his/c-myc tag at the C-terminus (named TG5(C) (a, b)) or at the N-terminus (named TG5(N) (c, d)). (a) The activity of TG5(C) soluble fractions (15minutes,
1–24 hours) and the insoluble fraction was determined by measuring the incorporation of 3H-labeled putrescine into N,N-dimethylcasein. TG activity is
reported as picomoles of putrescine cross-linked with milligram of total protein per hour. The highest enzymatic activity was detected in the soluble fractions
extracted after 3 and 24hours of incubation with a 1% TX-100/1% NP-40 buffer. (b) Western blot analysis of soluble and insoluble C-terminal his-myc
TG5 fractions, using a specific anti-c-myc antibody, revealed full-length TG5 to be present almost exclusively in the insoluble one, while being present in
soluble fractions in a lesser amount. The 25-kDa fragment was not detected under these experimental conditions. (c) Activity of TG5(N) soluble fractions and
the insoluble fraction was determined as described before. Also in this case, the highest enzymatic activity was detected in soluble fractions extracted after
3 and 24 hours of incubation with a 1% TX-100/1% NP-40 buffer. (d) Western blot analysis of soluble and insoluble TG5(N) fractions, using a specific
anti-c-myc antibody, revealed full-length TG5 to be present almost exclusively in the insoluble fraction, while being absent in the soluble fractions.
A 53-kDa fragment is present in the fractions with high TG activity, suggesting that this cleaved form is responsible for most of the enzymatic activity.
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but gives us information about the sequence region involved
in proteolysis.
TG5 proteolytic activation in eukaryotic epithelial cells
Proteolytic activation in TG-family members is not unusual.
At least FXIII and TG3 are subjected to proteolysis from
specific proteases, generating more active forms. We wanted
to verify whether TG5 proteolytic activation present in the
baculovirus system also occurred in cellular systems where
TG5 is expressed at endogenous level, and has specific
functions. We transiently transfected HEK-293 cells (human
embryonic epithelial kidney) and HaCat (human immor-
talized keratinocytes; not shown) using a vector bearing
C-terminus his/c-myc-tagged TG5 cDNA and a pcDNA
vector as control (Figure 3b–d). Cells were initially lysed
with a 0.1% TX-100 buffer to get rid of other TGs expressed
in cells. The insoluble fraction was incubated with a
buffer containing 1% TX-100/NP-40 at different extraction
time periods ranging from 3 to 24 hours. Enzyme activity
was determined in both soluble and insoluble fractions
(Figure 3b). In HEK-293 cells, enzyme activity was similar
to TG5 activity observed in the baculovirus system, with
the highest values in fractions obtained after 3 and 24 hours
of extraction with buffer having TX-100/NP-40, with the
remaining insoluble TG5 fraction not as active as the soluble
fractions. Enzyme activity arising from other TGs had a very
low intensity. Similar results were obtained from HaCat cells
(not shown). TG5 exogenous activity was present in 24 hours
in 1% TX-100/NP-40 extract (Figure 3b). To detect both
28- and 53-kDa fragments, HEK-293 cells were transfected
with TG5(N) or TG5(C), respectively. Western blot analyses
of the 24-hour soluble extract, using anti-c-myc (Figure 3c)
and anti-TG5 antibodies (Figure 3d), were performed. Results
revealed, besides the full-length enzyme, 28- and 53-kDa
fragments, using the anti-c-myc antibody on TG5 (C) and
TG5 (N), respectively. Both the fragments were detected
using the specific anti-TG5 antibody (Figure 3d, lane 2),
indicating that TG5 was cleaved in HEK-293 cells.
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Figure 3. Activity determination and western blot analysis of HEK-293 cells transfected with TG5(N) or TG5(C) cDNAs. (a) Western blot analysis of
soluble and insoluble fractions of C-terminal his-myc TG5, using a polyclonal rat antibody specific for the protein produced in our laboratory, showed a
53-kDa band increasing in intensity in active fractions proportionally to the increasing activity (reported as specific activity below the western blot), whereas
the full-length protein was present only in the insoluble fraction showing very low TG-specific activity. (b) HEK-293 cells were transiently transfected using
a vector bearing C-terminal his/c-myc-tagged TG5 cDNA, TG5(C), and a pcDNA vector as control. Cells were initially lysed with a 0.1% TX-100 buffer in
order to get rid of other TGs expressed in cells. The insoluble fraction was incubated with a 1% TX-100/NP-40 buffer at different extraction times ranging
from 3 to 24 hours. Enzyme activity was determined in both soluble and insoluble fractions. In HEK-293 cells, enzyme activity was similar to TG5 activity
observed in the baculovirus system, with the highest values in fractions obtained after 24 hours of TX-100/NP-40 buffer extraction, with the remaining
insoluble TG5 fraction not as active as soluble fractions. (c) Western blot analysis of 24-hour extracted fraction of TG5(N) and TG5(C), using a polyclonal
rat antibody specific for the protein produced in our laboratory, detected 56- and 25-kDa bands for TG5(N)- and TG5(C)-transfected cells (lanes 3 and 2,
respectively). Lane 1 shows analysis for cells transfected with the empty vector. (d) Western blot analysis was repeated only for HEK-293 cells, using
24-hour soluble (lane 2) and insoluble (lane 3) extracted proteins, using anti-TG5 antibody. The 24-hour soluble fraction yielded full-length and 53/28-kDa
fragment enzyme, whereas the insoluble fraction contained only the 80-kDa TG5.
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DISCUSSION
Proteolytic activation of proteins by specific proteases has
already been observed for several members of the TG family
such as FXIII and TG3. In this work, we reported that TG5
is proteolytically activated. Full-length N- or C-terminal
his/c-myc TG5, expressed in the baculovirus system, gave
rise to 53- and 28-kDa fragments co-purified by IMAC with
the full-length 80-kDa enzyme. This has been interpreted as
a consequence of a proteolysis process that allows a protein
cleavage at about 2/3 of the enzyme sequence, yielding
a 28-kDa C-terminal fragment and an active 53-kDa
N-terminal fragment consisting of the enzyme N-terminus
and the catalytic domains.
As indicated by molecular weight, the C-terminus 28-kDa
fragment probably contains the b-barrel-1 and b-barrel-2
domains. Therefore, it is possible that the TG5 loop region is
involved in the proteolytic process, as described for TG3. It is
possible, by analogy with TG3 structural studies (Figure 4a
and b; Ahvazi et al., 2004b; Candi et al., 2004), that calcium
ion could interact with the active 53-kDa fragment, giving
rise to a coordination complex with conserved acidic resi-
dues Asp306, Asp308, and Asp330 in TG5, which correspond to
residues Asp301, Asp303, and Asp324 in TG3. Once bound,
calcium ion could lead to a conformational change and
consequently a channel opening with an exhibition of Trp241
and Trp333 residues (corresponding to Trp236 and Trp327
residues in TG3), buried in the inactive enzyme.
These two amino acids could facilitate the interaction
among the substrate and the active site, assisting to complete
the catalytic process.
TG5 loop (Ser492–Ser501) is not in homology with any other
TG; hence, no structure can be predicted using our models,
even though it can be supposed that this loop should be
situated in the outer side of the enzyme structure and could
be responsible for other peculiar properties of TG5, such as
its insolubility. However, enzyme solubility is not only
related to proteolytic cleavage, since the 53-kDa fragment
can be dissolved after at least 3 hours of incubation in non-
ionic detergents, still remaining in part in the insoluble
fraction. It is also probable that after proteolysis, the enzyme
fragments form a 28/53-kDa complex bound by hydrophobic
interactions, which are still able to interact with vimentin
network, the result being an insoluble complex. Immuno-
fluorescence studies with keratinocytes transfected with
TG5 (Candi et al., 2001, 2002) demonstrated that both
in proliferating cells and in cells induced to differentiate
through 10-O-tetradecanoylphorbol-13-acetate treatment,
TG5 always colocalizes with vimentin and no free enzyme
is revealed in the cytoplasm by anti-c-myc and anti-TG5
antibodies. The explanation for this result could be that the
28/53-kDa complex, generated after differentiation stimulus,
being indistinguishable from full-length protein, remains
anchored to vimentin filaments.
Purification methodologies adopted probably destroy the
28/53-kDa complex, causing the 53-kDa fragment to dissolve.
This study reveals that TG5 proteolytic fragments (28/53 kDa),
similar to TG1 (67/33/10 kDa), present both in cytoplasm
and bound to the membrane, and in the activated TG3
(50/27kDa), remain bound to each other after proteolysis.
Biochemical and functional characterization performed in
this work demonstrated that TG5 is a complex enzyme. The
insolubility of the enzyme as well as the proteolytic activation,
revealed in the recombinant baculovirus system and in mam-
malian epithelial cells in vitro, and possibly also in vivo,
makes TG5 more complex than expected, its expression and
activity being obviously well controlled in cells.
β-Sandwich
β-Barrel-2
β-Barrel1
Catalytic 
core
C277
W241
W333
H336
D359
Figure 4. Model of human TG5 structure. (a) A ribbon image of the model of human TG5 structure. The two domains, b-sandwich and the catalytic
core (light blue), comprise the 53-kDa fragment. b-Barrel-1 and b-barrel-2 (forest green) account for the 28-kDa fragment. (b) The surface of the model structure
of activated human TG5. Hydrophobic and glycine residues are colored gray, positively charged residues in blue, and negatively charged residues in red.
All other polar residues are in slate. Aromatic residues are colored orange. Cysteines are in yellow. The inset shows the side-chain atoms of the catalytic
triad residues Cys277, His336, and Asp359, and the side-chain atoms of Trp241 and Trp333 are shown in ball-and-stick representation.
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MATERIALS AND METHODS
Reagents
All reagents were of chemical analytical grade. The origin of
individual reagents is indicated.
Recombinant baculovirus purification
Recombinant baculovirus TG5 plasmids with his-myc at the N-and
C-termini were obtained as described previously (Candi et al.,
2001).To extract active TG5 enzyme, insect cells were lysed by
sonication on ice in a buffer containing 20mM Tris-HCl, pH 8.5,
100mM NaCl, 1mM EDTA, 1mM dithiothreitol, and the protease
inhibitor AEBSF (1mM) (Sigma, St Louis, MO). The lysate was kept
for 15minutes on ice and centrifuged at 10,000 g for 20minutes at
4 1C. The cytosol was removed and the pellet was washed twice for
1 hour on ice in the same buffer containing 1% TX-100, 1% NP-40
(Sigma), and 10mM dithiothreitol. The active TG5 enzyme was
extracted after incubation in the same buffer at different time periods
(1–24 hours) at 4 1C. In some cases, this was followed by
immobilized-metal affinity chromatography (Talon Resin; Clontech,
Palo Alto, CA). The conditions for purification were the following:
binding of TG5 extract in the buffer described above with pre-
equilibrated cobalt IMAC resin for 1 hour at room temperature, three
washes with the same buffer without detergents, and elution with the
addition of 100mM imidazole to the washing buffer. Imidazole did
not interfere with TG activity measurements.
Transfection and western blot analysis
Sub-confluent HaCat (human immortalized keratinocytes) and HEK-
293 (human embryonic kidney) in 10-cm dishes were transfected
with 15 mg of total DNA (C-terminal his-myc TG5 and N-terminal
his-myc TG5 vectors) using 30 ml of lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA). The cells were harvested 24 hours after
transfection and lysed by sonication on ice in a buffer containing
50mM Tris-HCl, pH 8.5, 100mM NaCl, 1mM EDTA, 1mM
dithiothreitol, 1mM AEBSF, 1% TX-100 and 1% NP-40. The lysate
was kept for 1 hour on ice and centrifuged at 10,000 g for 20minutes
at 4 1C. The extracted proteins (30 mg) were separated by SDS–
polyacrylamide gel electrophoresis and transferred onto polyvinyl-
idene difluoride membranes; blots were kept in blocking solution for
2 hours and incubated for 2 hours with shaking at room temperatue
with the following primary antibodies: polyclonal anti-TG5 antibody
(Candi et al., 2002, 1:100 in blocking solution) and monoclonal anti-
c-myc antibody (1:1,000 in blocking solution; Santa Cruz Biotechno-
logy Inc., Santa Cruz, CA). After three washes in phosphate-buffered
saline–Tween-20 (0.1%), horseradish peroxidase-conjugated second-
ary antibodies (goat anti-mouse and anti-rat; Bio-Rad, Hercules, CA)
were added (1:10,000 in blocking solution). The proteins were
detected by enhanced chemiluminiscence.
Enzyme assay
TG activity was determined by measuring incorporation of 3H-
labeled putrescine (Amersham Pharmacia Biotech, New York,
NY) into N,N-dimethylcasein (Sigma). The reaction mixtures
contained 100mM Tris-HCl, pH 8.5, 100mM NaCl, 5mM dithio-
threitol, 10mM CaCl2, 25 ml of casein (12.5mg/ml), and 0.2mM
putrescine containing 1mCi of 3H-labeled putrescine. Cell lysates
(100 ng of total protein) were incubated in a final volume of 100ml at
37 1C. After 10minutes of incubation, the reaction was stopped by
spotting 25-ml aliquots onto Whatman 3MM filter paper. Unbound
3H-labeled putrescine was removed by washing with large volumes
of 15, 10, and 5% trichloroacetic acid and absolute ethanol. Filters
were then air-dried and radioactivity was measured by liquid
scintillation counting. TG assays were performed, for the most
part, in triplicate. As control, TG activity was also measured in
un-transfected cell lysates.
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